Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Cyproterone acetate (CPA) is an androgen receptor antagonist.1 It binds to human androgen receptors (Ki = 14 nM) and inhibits dihydrotestosterone-induced androgen receptor activation in CV-1 cells (IC50 = 26 nM). CPA (30 mg/kg) decreases ventral prostate weight in castrated immature rats. It also suppresses accessory sexual glands and fertility in adult male rats when administered at a dose of 10 mg/kg.2 CPA (0.3 µM) also induces apoptosis in primary adult female rat hepatocytes.3 Formulations containing cyproterone acetate have been used in the treatment of androgenization in females.
WARNING This product is not for human or veterinary use.
1. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-
2. Comparison of the effects of cyproterone, cyproterone acetate and oestradiol on testicular function, accessory sexual glands and fertility in a long-
3. Sex-